Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Efficacy of Belantamab Mafodotin + Bortezomib + Dexamethasone (BVd) Compared to Alternative Regimens in 2L+ Relapsed/Refractory Multiple Myeloma (RRMM): A Network Meta-analysis of Randomized Trials
Paula Rodríguez-Otero, MD, PhD (she/her/hers)
Associate Professor
Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
Pamplona, Navarra, Spain